Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health Nabs CE Mark for COVID-19, COVID/Flu Molecular Tests

NEW YORK – Lucira Health announced on Monday that both its COVID-19 and combination COVID-19 and influenza A/B molecular tests have received CE marking.

Both nucleic acid amplification tests run on Lucira's portable device, which has no separate instrument or reader, and return results from a nasal swab in 30 minutes. The COVID-19-only test is currently available in the US, Canada, Singapore, Israel, and Taiwan. It received Emergency Use Authorization from the US Food and Drug Administration in November 2020 for prescription home use and in CLIA-waived settings and got EUA for over-the-counter use in April 2021. 

The Emeryville, California-based company plans to make the combo test available in the EU beginning in the third quarter of 2022, before the Northern Hemisphere's influenza season. Submissions to other regulatory agencies, including the FDA and Health Canada, are planned for Q2, and decisions are expected before the upcoming flu season, Lucira said in a statement. 

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.